Bayer Management Board Chairman Dekkers looks on at a news conference in Leverkusen
Ina Fassbender
Bayer Management Board Chairman Marijn Dekkers looks on at a news conference in Leverkusen February 28, 2014. REUTERS/Ina Fassbender
updated 6/23/2014 7:48:21 AM ET 2014-06-23T11:48:21

FRANKFURT (Reuters) - Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of hemophilia A, marking renewed interest in an approach to tackle the cause of diseases on a cellular level.

Gene therapy involves inserting corrective genes into malfunctioning cells to get them to work again without further use of drugs. Dimension has been looking into using viruses to carry the genes to the affected cells.

(Editing by Jason Neely)

(c) Copyright Thomson Reuters 2014. Click For Restrictions - http://about.reuters.com/fulllegal.asp

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments